N-methyl-4-isoleucine cyclosporine attenuates CCl4-induced liver fibrosis in rats by interacting with cyclophilin B and D

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 558-567

  Wang, Hui ^a   Zhang, Yuguo ^a   Wang, Tailing ^b   You, Hong ^a   Jia, Jidong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Cyclophilin B; Cyclophilin D; Liver fibrosis; N methyl 4 isoleucine cyclosporine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN; COLLAGEN TYPE 3; COLLAGENASE 3; CYCLOPHILIN B; CYCLOPHILIN D; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; HYDROXYPROLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ACTIVATION; CONTROLLED STUDY; DRUG MEGADOSE; FIBROGENESIS; GENE EXPRESSION; GENE SEQUENCE; HEPATITIS; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCORING SYSTEM; STELLATE CELL;

EID: 79951612773     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06406.x     Document Type: Article

References (43)

1. Steinkasserer A, Harrison R, Billich A etal. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J. Virol. 1995; 69: 814-24.
2. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
3. Xia WL, Shen Y, Zheng SS. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat. Dis. Int. 2005; 4: 18-22.
4. Kawasaki H, Mocarski ES, Kosugi I, Tsutsui Y. Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells. J. Virol. 2007; 81: 9013-23.
5. Argaud L, Gateau-Roesch O, Muntean D etal. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J. Mol. Cell. Cardiol. 2005; 38: 367-74.
6. Borvak J, Chou CS, Van Dyke G, Rosenwirth B, Vitetta ES, Ramilo O. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25-quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. J. Infect. Dis. 1996; 174: 850-3.
7. Zhong Z, Theruvath TP, Currin RT, Waldmeier PC, Lemasters JJ. NIM811, a mitochondrial permeability transition inhibitor, prevents mitochondrial depolarization in small-for-size rat liver grafts. Am. J. Transplant. 2007; 7: 1103-11.
8. Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol. Pharmacol. 2002; 62: 22-9.
9. Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J. Virol. 2003; 77: 7713-19.
10. Watashi K, Ishii N, Hijikata M etal. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell. 2005; 19: 111-22.
11. Rehman H, Ramshesh VK, Theruvath TP etal. NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice. J. Pharmacol. Exp. Ther. 2008; 327: 699-706.
12. Kohjima M, Enjoji M, Higuchi N etal. NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2007; 27: 1273-81.
13. Liu XY, Yu LX, Fu SJ etal. Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 1090-2.
14. Fan S, Weng CF. Co-administration of cyclosporine an alleviates thioacetamide-induced liver injury. World J. Gastroenterol. 2005; 11: 1411-19.
15. Ma S, Boerner JE, TiongYip C etal. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 2006; 50: 2976-82.
16. Ciesek S, Steinmann E, Wedemeyer H etal. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009; 50: 1638-45.
17. Kim J, Choi TG, Ding Y etal. Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J. Cell. Sci. 2008; 121: 3636-48.
18. Duina AA, Chang HC, Marsh JA, Lindquist S, Gaber RF. A cyclophilin function in Hsp90-dependent signal transduction. Science 1996; 274: 1713-15.
19. Freeman BC, Toft DO, Morimoto RI. Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23. Science 1996; 274: 1718-20.
20. Melchior A, Denys A, Deligny A, Mazurier J, Allain F. Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp. Cell. Res. 2008; 314: 616-28.
21. Heck JA, Meng X, Frick DN. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase. Biochem. Pharmacol. 2009; 77: 1173-80.
22. Heitman J, Cullen BR. Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral Achilles heel? Mol. Cell. 2005; 19: 145-6.
23. Kantrow SP, Tatro LG, Piantadosi CA. Oxidative stress and adenine nucleotide control of mitochondrial permeability transition. Free Radic. Biol. Med. 2000; 28: 251-60.
24. Mbye LH, Singh IN, Sullivan PG, Springer JE, Hall ED. Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. Exp. Neurol. 2008; 209: 243-53.
25. Hui AY, Leung WK, Chan HL etal. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int. 2006; 26: 125-36.
26. Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S, Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005; 129: 2009-31.
27. Urtasun R, Conde de la Rosa L, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin. Liver Dis. 2008; 12: 769-90, viii.
28. Zhao XY, Wang BE, Li XM, Wang TL. Newly proposed fibrosis staging criterion for assessing carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents. Pathol. Int. 2008; 58: 580-8.
29. Chang D, Wang TY, Li HC, Wei JC, Song JX. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis. Esophagus. 2007; 20: 491-6.
30. Fallowfield JA, Iredale JP. Targeted treatments for cirrhosis. Expert. Opin. Ther. Targets. 2004; 8: 423-35.
31. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 1993; 328: 1828-35.
32. Friedman SL. Cytokines and fibrogenesis. Semin. Liver Dis. 1999; 19: 129-40.
33. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000; 275: 2247-50.
34. Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. Expert. Rev. Mol. Med. 2003; 5: 1-23.
35. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin. Gastroenterol. Hepatol. 2005; 3: 95-107.
36. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-7.
37. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J. Gastroenterol. Hepatol. 1999; 14: 618-33.
38. Luo L, Zhou A. Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase-2 and its inhibitor tissue inhibitors of metalloproteinases-2 and transforming growth factor beta1 in rats with carbon tetrachloride-induced liver injury. J. Gastroenterol. Hepatol. 2009; 24: 1070-6.
39. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z. Gastroenterol. 2006; 44: 57-66.
40. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008; 88: 125-72.
41. Billich A, Hammerschmid F, Peichl P etal. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 1995; 69: 2451-61.
42. Flisiak R, Horban A, Gallay P etal. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47: 817-26.
43. Yu J, Hui AY, Chu ES etal. The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. Liver Int. 2009; 29: 25-36.